Patents by Inventor Martin Fussenegger
Martin Fussenegger has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20210222129Abstract: The present invention relates to expression system for establishing a transgenic differentiation-control network useful for controlling cell differentiation.Type: ApplicationFiled: December 21, 2016Publication date: July 22, 2021Inventors: Martin FUSSENEGGER, Pratik SAXENA, Henryk ZULEWSKI
-
Publication number: 20200216514Abstract: Provided herein are generalized extracellular molecule sensors (GEMSs) and polynucleotides encoding the GEMSs. Also provided herein are methods of making and using the GEMSs, such as therapeutic and diagnostic methods.Type: ApplicationFiled: January 8, 2020Publication date: July 9, 2020Inventors: Martin Fussenegger, Leo Scheller, Tobias Strittmatter, David W. Fuchs, Daniel Bojar
-
Publication number: 20190282710Abstract: The present invention relates to ?-cell-mimetic cells. Methods for producing ?-cell-mimetic cells as well as methods of use of ?-cell-mimetic cells as a medicament and methods of use of ?-cell-mimetic cells for the prevention, delay of progression or treatment of a metabolic disease in a subject are also provided.Type: ApplicationFiled: July 17, 2017Publication date: September 19, 2019Inventors: Martin FUSSENEGGER, Mingqi XIE
-
Patent number: 10415054Abstract: The invention relates to vectors and mammalian cells in a system useful for switching on or switching off gene expression in response to fatty acids, and a method of treating diet-induced obesity. In particular, a synthetic intracellular lipid-sensing receptor was constructed that constantly monitors blood fatty acid levels, processes diet-associated hyperlipidemia and coordinates reversible and adjustable expression of the anorectic peptide hormone pramlintide to reduce dietary intake, blood fat levels and body weight.Type: GrantFiled: February 3, 2014Date of Patent: September 17, 2019Assignee: ETH ZURICHInventors: Katrin Rossger, Martin Fussenegger
-
Publication number: 20150376647Abstract: The invention relates to vectors and mammalian cells in a system useful for switching on or switching off gene expression in response to pH and gaseous carbon dioxide, taking advantage of signal transduction of the human proton-activated cell-surface receptor TDAG8, OGR1 and/or GPR4 and related receptors to chimeric promoters containing cAMP-response elements. The systems according to the invention can be used to precisely monitor culture pH within the physiologic range, or also to adjust expression by gaseous C02 which shifts the C02-bicarbonate balance towards hydrogen ions. Production of biopharmaceuticals of engineered cells cultivated in a bioreactor setup can be induced by gaseous C02. Also, implanting engineered cells provide novel treatment strategies for acidosis-related disorders and type 1 diabetes.Type: ApplicationFiled: February 10, 2014Publication date: December 31, 2015Inventors: David Auslaender, Simon Auslaender, Martin Fussenegger
-
Publication number: 20150368666Abstract: The invention relates to vectors and mammalian cells in a system useful for switching on or switching off gene expression in response to fatty acids, and a method of treating diet-induced obesity. In particular, a synthetic intracellular lipid-sensing receptor was constructed that constantly monitors blood fatty acid levels, processes diet-associated hyperlipidemia and coordinates reversible and adjustable expression of the anorectic peptide hormone pramlintide to reduce dietary intake, blood fat levels and body weight.Type: ApplicationFiled: February 3, 2014Publication date: December 24, 2015Inventors: Katrin Rössger, Martin Fussenegger
-
Patent number: 9050295Abstract: The invention relates to a pharmaceutical composition comprising a compound preventing EthR from binding to the ethA promoter, for example a compound of formula 1 wherein R1 is optionally substituted phenyl or optionally substituted pyridyl; R2 (CH2)n wherein n is 1, 2, 3 or 4; R3 is CH3(CH2)m wherein m is 0, 1, 2 or 3; X1 is O, S, NH, N(CH3) or CH2; and X2 is O, S or NH; in particular 2-phenylethyl butyrate, and a thioamide or thiourea of formula 2 wherein R4 is optionally substituted phenyl, optionally substituted pyridyl, optionally substituted indolyl, —NR7R8; or —NH—N?CH—R9; and substituents R5 to R9 have the meanings indicated in the description, in particular ethionamide. The pharmaceutical composition is useful, e.g., in the treatment of multidrug-resistant tuberculosis.Type: GrantFiled: November 25, 2008Date of Patent: June 9, 2015Assignee: ETH ZurichInventors: Martin Fussenegger, Wilfried Weber, Ronald Schoenmakers
-
Patent number: 8912329Abstract: The invention relates to a pharmaceutical composition comprising a compound of formula (1) wherein R1 is optionally substituted phenyl, optionally substituted pyridyl or optionally substituted indolyl; R2 is (CH2)n wherein n is 0, 1, 2, 3 or 4; R3 is (CH2)mR3A wherein m is 0, 1, 2, 3 or 4, and R3A is methyl, isopropyl, tert-butyl, OCH3, OH, optionally substituted phenoxy, C?CH, C?N, optionally substituted phenyl, furanyl or thienyl; A is a ring containing X1 with the meaning O, S, NH, N(CH3) or CH2; and X2 is O, S or NH; and a compound of formula (2) wherein R4 is optionally substituted phenyl, optionally substituted pyridyl, optionally substituted indolyl, —NR7R8; or —NH—N?CH—R9; and substituents R5 to R9 have the meanings indicated in the description, in particular ethionamide. The pharmaceutical composition is useful, e.g., in the treatment of multidrug-resistant tuberculosis.Type: GrantFiled: June 25, 2010Date of Patent: December 16, 2014Assignee: Bioversys AGInventors: Ronald Schoenmakers, Wilfried Weber, Marc Gitzinger, Martin Fussenegger, Marcel Tigges, Peter Schneider
-
Publication number: 20140059709Abstract: The invention relates to vectors and mammalian cells in a system useful for switching on or switching off gene expression in response to uric acid. In a particular embodiment the invention relates to a mammalian cell useful in detecting and/or degrading a harmful excess of uric acid comprising (a) a vector comprising a genetic code for the uricase sensor-regulator HucR from Deinococcus radiodurans R1 fused to a transactivation domain or a transrepressor domain; and (b) a vector comprising the corresponding operator sequence hucO from Deinococcus radiodurans R1 specifically binding the bacterial uric acid sensor-regulator HucR, a promoter and a polynucleotide coding for an endogenous or exogenous protein, e.g. a protein interacting with uric acid.Type: ApplicationFiled: October 3, 2013Publication date: February 27, 2014Applicant: ETH ZURICHInventors: Christian KEMMER, Wilfried WEBER, Martin FUSSENEGGER
-
Patent number: 8653046Abstract: The invention relates to the use of a skin permeating compound such as phloretin for controlling transgene expression under control of the Pseudomonas putida DOT-T1E-derived bacterial repressor TtgR, to a vector comprising the genetic code for the repressor TtgR fused to a transactivation or a transrepressor domain, to a vector comprising a TtgR-specific operator sequence (OTtgR), a promoter and a polynucleotide coding for an endogenous or exogenous protein, and to a mammalian cell transiently or constitutively transfected with the mentioned vectors, and to mammals comprising such cells in nano- or microcontainers.Type: GrantFiled: April 1, 2010Date of Patent: February 18, 2014Assignee: ETH ZurichInventors: Martin Fussenegger, Marc Gitzinger
-
Publication number: 20130210074Abstract: The invention concerns the field of cell culture technology. It concerns production host cell lines with increased expression of ribosomal RNA (rRNA) achieved through reducing expression of NoCR proteins, especially of TIP-5. Those cell lines have improved secretion and growth characteristics in comparison to control cell lines. The invention further concerns a method of producing proteins using the cells generated by the described method.Type: ApplicationFiled: April 9, 2013Publication date: August 15, 2013Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBHInventors: Lore FLORIN, Barbara ENENKEL, Martin FUSSENEGGER, Hitto KAUFMANN, Raffaella SANTORO
-
Patent number: 8506950Abstract: The invention relates to microcapsules consisting of a polymer degradable by a polypeptide comprising a drug or other compound of interest and a genetically engineered cell expressing said polypeptide in response to a triggering compound, and to methods of directed release of the compound of interest. The preferred polymer is optionally modified cellulose sulfate/poly-diallyl-dimethyl-ammonium chloride. Such microcapsules are non-toxic, do not elicit an immunological response and have an extended half-life time in mammals. The expression system for cellulase is, for example, based on TET and doxycycline, or E.REX and erythromycin. In another example, expression of cellulase is triggered by luteinizing hormone, which can be used for artificial insemination with microcapsules carrying sperm.Type: GrantFiled: September 6, 2012Date of Patent: August 13, 2013Assignees: ETH Zurich, SwissgeneticsInventors: Christian Kemmer, David Fluri, Ulrich Witschi, Wilfried Weber, Martin Fussenegger
-
Patent number: 8388945Abstract: The invention relates to microcapsules consisting of a polymer degradable by a polypeptide comprising a drug or other compound of interest and a genetically engineered cell expressing said polypeptide in response to a triggering compound, and to methods of directed release of the compound of interest. The preferred polymer is optionally modified cellulose sulfate/poly-diallyl-dimethyl-ammonium chloride. Such microcapsules are non-toxic, do not elicit an immunological response and have an extended half-life time in mammals. The expression system for cellulase is, for example, based on TET and doxycycline, or E.REX and erythromycin. In another example, expression of cellulase is triggered by luteinizing hormone, which can be used for artificial insemination with microcapsules carrying sperm.Type: GrantFiled: July 10, 2009Date of Patent: March 5, 2013Assignees: ETH Zurich, SwissgeneticsInventors: Christian Kemmer, David Fluri, Ulrich Witschi, Wilfried Weber, Martin Fussenegger
-
Publication number: 20130045190Abstract: The invention relates to microcapsules consisting of a polymer degradable by a polypeptide comprising a drug or other compound of interest and a genetically engineered cell expressing said polypeptide in response to a triggering compound, and to methods of directed release of the compound of interest. The preferred polymer is optionally modified cellulose sulfate/poly-diallyl-dimethyl-ammonium chloride. Such microcapsules are non-toxic, do not elicit an immunological response and have an extended half-life time in mammals. The expression system for cellulase is, for example, based on TET and doxycycline, or E.REX and erythromycin. In another example, expression of cellulase is triggered by luteinizing hormone, which can be used for artificial insemination with microcapsules carrying sperm.Type: ApplicationFiled: September 6, 2012Publication date: February 21, 2013Inventors: Christian KEMMER, David Fluri, Ulrich Witschi, Wilfried Weber, Martin Fussenegger
-
Publication number: 20120190065Abstract: The invention concerns the field of cell culture technology. It concerns production host cell lines with increased expression of ribosomal RNA (rRNA) achieved through introduction of nucleic acids encoding UBF or reducing expression of NoRC proteins, especially of TIP-5. Those cell lines have improved secretion and growth characteristics in comparison to control cell lines. The invention further concerns a method of producing proteins using the cells generated by the described method.Type: ApplicationFiled: May 12, 2010Publication date: July 26, 2012Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBHInventors: Lore Florin, Barbara Enenkel, Martin Fussenegger, Hitto Kaufmann, Raffaella Santoro
-
Publication number: 20120101080Abstract: The invention relates to a pharmaceutical composition comprising a compound of formula (1) wherein R1 is optionally substituted phenyl, optionally substituted pyridyl or optionally substituted indolyl; R2 is (CH2)n wherein n is 0, 1, 2, 3 or 4; R3 is (CH2)mR3A wherein m is 0, 1, 2, 3 or 4, and R3A is methyl, isopropyl, tert-butyl, OCH3, OH, optionally substituted phenoxy, C?CH, C?N, optionally substituted phenyl, furanyl or thienyl; A is a ring containing X1 with the meaning O, S, NH, N(CH3) or CH2; and X2 is O, S or NH; and a compound of formula (2) wherein R4 is optionally substituted phenyl, optionally substituted pyridyl, optionally substituted indolyl, —NR7R8; or —NH—N?CH—R9; and substituents R5 to R9 have the meanings indicated in the description, in particular ethionamide. The pharmaceutical composition is useful, e.g., in the treatment of multidrug-resistant tuberculosis.Type: ApplicationFiled: June 25, 2010Publication date: April 26, 2012Applicant: BioVersys AGInventors: Ronald Schoenmakers, Wilfried Weber, Marc Gitzinger, Martin Fussenegger, Marcel Tigges, Peter Schneider
-
Publication number: 20120066778Abstract: The invention relates to vectors and mammalian cells in a system useful for switching on or switching off gene expression in response to uric acid. In a particular embodiment the invention relates to a mammalian cell useful in detecting and/or degrading a harmful excess of uric acid comprising (a) a vector comprising a genetic code for the uricase sensor-regulator HucR from Deinococcus radiodurans R1 fused to a transactivation domain or a transrepressor domain; and (b) a vector comprising the corresponding operator sequence hucO from Deinococcus radiodurans R1 specifically binding the bacterial uric acid sensor-regulator HucR, a promoter and a polynucleotide coding for an endogenous or exogenous protein, e.g. a protein interacting with uric acid.Type: ApplicationFiled: May 6, 2010Publication date: March 15, 2012Inventors: Christian Kemmer, Wilfried Weber, Martin Fussenegger
-
Publication number: 20120029074Abstract: The invention relates to the use of a skin permeating compound such as phloretin for controlling transgene expression under control of the Pseudomonas putida DOT-T1E-derived bacterial repressor TtgR, to a vector comprising the genetic code for the repressor TtgR fused to a transactivation or a transrepressor domain, to a vector comprising a TtgR-specific operator sequence (OTtgR), a promoter and a polynucleotide coding for an endogenous or exogenous protein, and to a mammalian cell transiently or constitutively transfected with the mentioned vectors, and to mammals comprising such cells in nano- or microcontainers.Type: ApplicationFiled: April 1, 2010Publication date: February 2, 2012Inventors: Martin Fussenegger, Marc Gitzinger
-
Publication number: 20110177162Abstract: The invention relates to microcapsules consisting of a polymer degradable by a polypeptide comprising a drug or other compound of interest and a genetically engineered cell expressing said polypeptide in response to a triggering compound, and to methods of directed release of the compound of interest. The preferred polymer is optionally modified cellulose sulfate/poly-diallyl-dimethyl-ammonium chloride. Such microcapsules are non-toxic, do not elicit an immunological response and have an extended half-life time in mammals. The expression system for cellulase is, for example, based on TET and doxycycline, or E.REX and erythromycin. In another example, expression of cellulase is triggered by luteinizing hormone, which can be used for artificial insemination with microcapsules carrying sperm.Type: ApplicationFiled: July 10, 2009Publication date: July 21, 2011Inventors: Christian Kemmer, David Fluri, Ulrich Witschi, Wilfried Weber, Martin Fussenegger
-
Publication number: 20110151006Abstract: The present invention relates to a hydrogel comprising a polymer, a first polypeptide and a polypeptide binding partner, wherein the polypeptide binding partner is a second polypeptide, a nucleic acid or a small molecule, and wherein the interaction between the first polypeptide and the polypeptide binding partner stabilizes the hydrogel and is modulated by the addition of a modulating compound. A drug may be physically entrapped in the hydrogel, bound to the polymer forming the hydrogel structure, or bound to the first polypeptide or the polypeptide binding partner, and then be set free on addition of the modulating compound. Such a hydrogel comprising a drug may be injected into a patient, and drug release modulated by orally administering the modulating compound.Type: ApplicationFiled: June 5, 2009Publication date: June 23, 2011Inventors: Wilfried Weber, Martin Fussenegger, Ronald Schoenmakers